Drug Profile
Idraparinux sodium
Alternative Names: Idraparinux; SANORG 34006; SR 34006Latest Information Update: 20 Oct 2009
Price :
$50
*
At a glance
- Originator Organon
- Developer sanofi-aventis
- Class Anticoagulants; Antithrombotics; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the Thromboses therapeutic trials section
- 12 Sep 2005 sanofi-aventis has ceased enrolment in the AMADEUS trial for the prevention of venous thromboembolism in patients with atrial fibrillation
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis